Alimera Sciences (ALIM) News Today → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free ALIM Stock Alerts $3.20 -0.08 (-2.44%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 8:25 AM | marketbeat.comHC Wainwright Research Analysts Cut Earnings Estimates for Alimera Sciences, Inc. (NASDAQ:ALIM)Alimera Sciences, Inc. (NASDAQ:ALIM - Free Report) - Analysts at HC Wainwright decreased their Q3 2024 earnings estimates for Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings per share of (May 16 at 10:58 AM | markets.businessinsider.comRobust Growth and Promising Trials: Buy Rating for Alimera SciencesMay 16 at 8:29 AM | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $6.00 price target on shares of Alimera Sciences in a report on Thursday.May 16 at 4:30 AM | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Short Interest Up 8.4% in AprilMay 15 at 2:30 PM | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Issues Earnings Results, Misses Estimates By $0.08 EPSAlimera Sciences (NASDAQ:ALIM - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $23.01 million during the quarter, compared to analyst estimates of $23.72 million. Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. During the same period in the previous year, the firm posted ($0.71) EPS.May 15 at 3:47 AM | finance.yahoo.comAlimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...May 14 at 7:30 AM | globenewswire.comAlimera Sciences Reports First Quarter 2024 ResultsMay 12, 2024 | americanbankingnews.comAlimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on TuesdayMay 7, 2024 | finance.yahoo.comAlimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesMay 7, 2024 | marketbeat.comAlimera Sciences (ALIM) to Release Earnings on TuesdayAlimera Sciences (NASDAQ:ALIM) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591841)April 30, 2024 | finance.yahoo.comAlimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateApril 30, 2024 | marketbeat.comStockNews.com Lowers Alimera Sciences (NASDAQ:ALIM) to HoldStockNews.com cut Alimera Sciences from a "buy" rating to a "hold" rating in a report on Tuesday.April 22, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Alimera Sciences from a "hold" rating to a "buy" rating in a research report on Monday.April 13, 2024 | marketbeat.comAlimera Sciences, Inc. (NASDAQ:ALIM) Sees Large Growth in Short InterestAlimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 108,800 shares, a growth of 26.8% from the March 15th total of 85,800 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is presently 1.3 days.April 12, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Alimera Sciences from a "buy" rating to a "hold" rating in a report on Friday.April 4, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Lifted to Buy at StockNews.comStockNews.com upgraded shares of Alimera Sciences from a "hold" rating to a "buy" rating in a research note on Thursday.April 3, 2024 | finance.yahoo.comLuckie & Company Acquires Marbury Creative GroupApril 3, 2024 | bizjournals.comLuckie & Co. acquires Atlanta marketing agencyMarch 29, 2024 | marketbeat.comAlimera Sciences, Inc. (NASDAQ:ALIM) Short Interest UpdateAlimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 85,800 shares, a decline of 27.7% from the February 29th total of 118,600 shares. Based on an average trading volume of 82,500 shares, the days-to-cover ratio is currently 1.0 days.March 26, 2024 | finance.yahoo.comOcular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031March 25, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Receives New Coverage from Analysts at Maxim GroupMaxim Group assumed coverage on Alimera Sciences in a research report on Monday. They issued a "buy" rating and a $10.00 target price for the company.March 21, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Stock Price Crosses Above Two Hundred Day Moving Average of $3.53Alimera Sciences (NASDAQ:ALIM) Stock Crosses Above 200-Day Moving Average of $3.53March 20, 2024 | finance.yahoo.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | finance.yahoo.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | globenewswire.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 18, 2024 | msn.comMizuho downgrades Amylyx to Neutral after ALS trial setbackMarch 10, 2024 | realmoney.thestreet.comAlimera Sciences price target raised by $1 at H.C. Wainwright, here's whyMarch 9, 2024 | seekingalpha.comAlimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical TrialsMarch 8, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Issues Earnings ResultsAlimera Sciences (NASDAQ:ALIM - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.09). The business had revenue of $26.31 million for the quarter, compared to analysts' expectations of $25.10 million. During the same period in the previous year, the company earned ($0.54) earnings per share.March 8, 2024 | finance.yahoo.comQ4 2023 Alimera Sciences Inc Earnings CallMarch 7, 2024 | investorplace.comALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 7, 2024 | globenewswire.comAlimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comA Preview Of Alimera Sciences's EarningsMarch 6, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To ProfitabilityMarch 6, 2024 | marketbeat.comWorth Venture Partners LLC Purchases New Position in Alimera Sciences, Inc. (NASDAQ:ALIM)Worth Venture Partners LLC purchased a new stake in Alimera Sciences, Inc. (NASDAQ:ALIM - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 593,709 shares of the biopharmaceutical company's stock, valued at approximately $1,84March 3, 2024 | marketbeat.comAlimera Sciences, Inc. (NASDAQ:ALIM) Sees Significant Drop in Short InterestAlimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 276,800 shares, a drop of 9.2% from the January 31st total of 304,900 shares. Based on an average daily volume of 99,500 shares, the short-interest ratio is currently 2.8 days.March 1, 2024 | marketbeat.comAlimera Sciences (ALIM) Set to Announce Earnings on ThursdayAlimera Sciences (NASDAQ:ALIM) will be releasing earnings before the market opens on Thursday, March 7, Zacks reports.February 29, 2024 | finance.yahoo.comAlimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate UpdateFebruary 16, 2024 | marketbeat.comAIGH Capital Management LLC Takes $7.36 Million Position in Alimera Sciences, Inc. (NASDAQ:ALIM)AIGH Capital Management LLC bought a new position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,372,572 shares of the biopFebruary 10, 2024 | msn.comAlimera Sciences Launches 2024 Equity Inducement PlanFebruary 8, 2024 | finance.yahoo.comThe UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®February 8, 2024 | marketbeat.comAlimera Sciences (NASDAQ:ALIM) Shares Pass Above 200 Day Moving Average of $3.46Alimera Sciences (NASDAQ:ALIM) Stock Price Passes Above 200-Day Moving Average of $3.46January 25, 2024 | finance.yahoo.comAlimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years agoJanuary 4, 2024 | finance.yahoo.comAlimera Completes Recruitment for the Synchronicity StudyJanuary 2, 2024 | marketwatch.comAlimera Sciences Names Elliot Maltz Chief Financial OfficerJanuary 2, 2024 | markets.businessinsider.comAlimera Sciences Names Elliot Maltz To Succeed Russell Skibsted As CFO Get Alimera Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Clinton Backing Biden Replacement??? (Ad)Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by August… Click here now for my urgent election forecast. ALIM Media Mentions By Week ALIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALIM News Sentiment▼0.050.53▲Average Medical News Sentiment ALIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALIM Articles This Week▼121▲ALIM Articles Average Week Get Alimera Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GLSI News Today GALT News Today RIGL News Today GOSS News Today CAPR News Today PRLD News Today SCPH News Today PRQR News Today LFCR News Today TELO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALIM) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
